Hospital Vall d'Hebron-ko ikertzaileekin lankidetzan egindako argitalpenak (19)

2025

  1. Metagenomic symphony of the intestinal ecosystem: How the composition affects the mind

    Brain, Behavior, and Immunity, Vol. 123, pp. 510-523

2024

  1. Cerebroprotective Effects of the TLR4-Binding DNA Aptamer ApTOLL in a Rat Model of Ischemic Stroke and Thrombectomy Recanalization

    Pharmaceutics, Vol. 16, Núm. 6

2023

  1. APRIL: A double-blind, placebo-controlled, randomized, Phase Ib/IIa clinical study of ApTOLL for the treatment of acute ischemic stroke

    Frontiers in Neurology, Vol. 14

  2. Safety and Efficacy of ApTOLL in Patients with Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial

    JAMA Neurology, Vol. 80, Núm. 8, pp. 779-788

  3. miR-203 drives breast cancer cell differentiation

    Breast Cancer Research, Vol. 25, Núm. 1

2022

  1. Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation

    Journal of experimental & clinical cancer research : CR, Vol. 41, Núm. 1, pp. 285

2021

  1. Defining a Target Population to Effectively Test a Neuroprotective Drug

    Stroke, Vol. 52, Núm. 2, pp. 505-510

  2. The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells

    Autophagy, Vol. 17, Núm. 6, pp. 1349-1366

2019

  1. Therapeutic targeting of HER2–CB 2 R heteromers in HER2-positive breast cancer

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, Núm. 9, pp. 3863-3872

  2. CIBERSAM: Ten years of collaborative translational research in mental disorders

    Revista de Psiquiatria y Salud Mental, Vol. 12, Núm. 1, pp. 1-8

  3. Erratum: Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer (Proceedings of the National Academy of Sciences of the United States of America (2019) 116 (3863–3872) DOI: 10.1073/pnas.1815034116)

    Proceedings of the National Academy of Sciences of the United States of America

2016

  1. The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase

    Clinical Cancer Research, Vol. 22, Núm. 10, pp. 2508-2519

2015

  1. Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes

    Cancer Cell, Vol. 28, Núm. 2, pp. 170-182

2012

  1. Guidelines for the use and interpretation of assays for monitoring autophagy

    Autophagy, Vol. 8, Núm. 4, pp. 445-544

2011

  1. Glaucoma patients present increased levels of diadenosine tetraphosphate, Ap4A, in the aqueous humour

    Experimental Eye Research, Vol. 92, Núm. 3, pp. 221-226

  2. Implication of the toll-like receptor 4 pathway in the response to interferon-β in multiple sclerosis

    Annals of Neurology, Vol. 70, Núm. 4, pp. 634-645

2009

  1. Plasma levels of 15d-PGJ2 are not altered in multiple sclerosis

    European Journal of Neurology, Vol. 16, Núm. 11, pp. 1197-1201

2006

  1. TNF-α converting enzyme (TACE) protein expression in different clinical subtypes of multiple sclerosis

    Journal of Neurology, Vol. 253, Núm. 6, pp. 701-706

2003

  1. Revisión de consenso. Neuroprotección farmacológica en la isquemia cerebral: ¿Es todavía una opción terapéutica?

    Neurologia, Vol. 18, Núm. 7, pp. 368-384